Preparation and Characterization of a Novel Optimum Modified Liquisolid Compact to Enhance the Dissolution Profile of Mifepristone
Riya Patel, Gayatri Patel
Abstract
Most drugs used to treat vaginal disorders are administered orally or parenterally.Mifepristone (MFP) is a Biopharmaceutical Classification System class IV drug that is currently used to abort pregnancies under 70 days long.To improve bioavailability, a modified liquisolid compact (MLSC) formulation has been proposed for vaginal administration for off-label treatment of uterine fibroids.The MLSC was prepared using ultrasonication with pre-screened excipients to minimize the bulk of the final formulation and enhance properties for commercial viability.The MLSC formulation was evaluated for physical properties (including morphology, uniformity, wettability) and in vitro dissolution of MFP.The results showed 85-90% of MFP was released in 90 mins at a pH range of 1.2-7.4,and dissolution in water supports pHindependent dissolution process.Faster dissolution at vaginal fluid pH may minimize the associated adverse effects of the dose.The physical modification of MFP as an MLSC formulation improved dissolution and absorption for potential vaginal administration.